Francisco Pasquel, MD
Endocrinology, Diabetes & Metabolism · Atlanta, GANPI 1417117003
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Merck at 35.5% of the total. Reporting peaked in 2019 at $20,624 and has fallen 75.9% since, to $4,968 in 2025. Among endocrinology, diabetes & metabolism clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 44 payments — averaging $910.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$14K
- Dexcom, Inc.$8K
- Eli Lilly$5K
- Abbott$5K
- Sanofi-aventis U.S. LLC$2K
- Boehringer Ingelheim Del Ecuador Cia. Ltda.$2K
- plus $4K from 4 others
Across 42 payments — averaging $8003.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tandem Diabetes Care, Inc.$219K
- Merck$85K
- Dexcom, Inc.$23K
- Insulet Corporation$9K
What the payments were for
- Consulting fees$15,32238%
- Speaking & faculty fees$21,65354%
- Travel & lodging$1,9355%
- Food & beverage$1,1053%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 16 | $14,235 |
| Dexcom, Inc. | 5 | $7,822 |
| Eli Lilly | 11 | $5,315 |
| Abbott | 4 | $4,968 |
| Sanofi-aventis U.S. LLC | 3 | $2,000 |
| Boehringer Ingelheim Del Ecuador Cia. Ltda. | 1 | $1,700 |
| Boehringer Ingelheim Peru S.a.c | 1 | $1,500 |
| Boehringer Ingelheim Mexico SA De CV | 1 | $1,400 |
| AstraZeneca | 1 | $1,074 |
| Novo Nordisk | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FreeStyle Libre$4,870
- DEXCOM G7 GSS (161)$4,760
- JARDIANCE$4,600
- DEXCOM G6 TRANSMITTER$3,062
- SOLIQUA 100/33$2,000
- FARXIGA$1,074
How this compares
$40,047 in reported general payments places this provider in the 90th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 124 | $138,033 |
| JardianceEmpagliflozin | 30 | $45,931 |
| TrulicityDulaglutide | 31 | $37,698 |
| FarxigaDapagliflozin Propanediol | 23 | $24,315 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $19,446 |
| MounjaroTirzepatide | 21 | $19,188 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $5,415 |
| Novolog FlexpenInsulin Aspart | 33 | $4,918 |
| Humalog Kwikpen U-100Insulin Lispro | 22 | $4,414 |
| Levemir FlexpenInsulin Detemir | 16 | $2,088 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 25 | $1,602 |
| Atorvastatin Calcium | 33 | $260 |
| Gabapentin | 26 | $139 |
| Amlodipine Besylate | 29 | $90 |
| Losartan Potassium | 24 | $86 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $32 | $138,033124 claims |
| AstraZenecaFarxiga | $1,074 | $24,31523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Atlanta
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Jonathan OwnbyAtlanta$291K
- Gulliermo UmpierrezAtlanta$63K
- Norman WelchAtlanta$25K
- Rachel DerrAtlanta$18K
- Kate WheelerAtlanta$17K
- John ZoraAtlanta$16K
- Ernest BeasleyAtlanta$14K
- Era ShahAtlanta$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.